Guggenheim Maintains ANI Pharmaceuticals(ANIP.US) With Buy Rating, Maintains Target Price $86
ANI Pharmaceuticals Price Target Maintained With a $86.00/Share by Guggenheim
ANI Pharmaceuticals Analyst Ratings
Leerink Partners Maintains ANI Pharmaceuticals(ANIP.US) With Buy Rating, Maintains Target Price $82
Jefferies Maintains ANI Pharmaceuticals(ANIP.US) With Buy Rating, Maintains Target Price $80
Strong Growth and Undervaluation Make ANI Pharmaceuticals a Buy
H.C. Wainwright Maintains ANI Pharmaceuticals(ANIP.US) With Buy Rating, Maintains Target Price $94
HC Wainwright & Co. Reiterates Buy on ANI Pharmaceuticals, Maintains $94 Price Target
Jefferies Initiates ANI Pharmaceuticals(ANIP.US) With Buy Rating, Announces Target Price $80
ANI Pharmaceuticals Price Target Announced at $85.00/Share by JP Morgan
ANI Pharmaceuticals Initiated at Overweight by JP Morgan
ANI Pharmaceuticals Analyst Ratings
J.P. Morgan Initiates ANI Pharmaceuticals(ANIP.US) With Buy Rating, Announces Target Price $85
ANI Pharmaceuticals Is Maintained at Buy by Guggenheim
Guggenheim Maintains ANI Pharmaceuticals(ANIP.US) With Buy Rating, Raises Target Price to $86
Leerink Partners Maintains ANI Pharmaceuticals(ANIP.US) With Buy Rating, Maintains Target Price $82
Truist Financial Maintains ANI Pharmaceuticals(ANIP.US) With Hold Rating
ANI Pharmaceuticals Price Target Maintained With a $94.00/Share by HC Wainwright & Co.
ANI Pharmaceuticals Analyst Ratings
H.C. Wainwright Maintains ANI Pharmaceuticals(ANIP.US) With Buy Rating, Maintains Target Price $94